NbTAST-01NCT07055594
A Study to Investigate Safety and Preliminary Efficacy of SOA101 in Adult Subjects With Advanced Solid Tumors
At risk: Primary endpoint(s) modified.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary endpoint(s) modified
- Eligibility criteria expanded, about 19 words
- Secondary endpoints: details revised at 1 of 4 entries
- Publications: details revised at 1 of 1 entry
- Minor Publications: details revised at 1 of 1 entryv4
- Minor Start date changed from estimate of Jul 2025 to Jul 30, 2025v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Maximum Tolerated Dose (MTD) of SOA101 for Phase I
Timeframe: from start until 3 months after the last dosing
Objective Response Rate (ORR) of SOA101 for Phase II
Timeframe: from start until 3 months after the last dosing
Secondary (4)
Area Under the Curve of SOA101 (AUC)
Maximum observed plasma concentration of SOA101 (Cmax)
Half-life of SOA101 (T1/2)
Overall Response Rate (ORR)
Arms and interventions
SOA101Experimental
Drugs: SOA101
Sites
1 site in 1 country
- China Medical University HospitalTaichung, Taiwan